Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
NCT ID: NCT00104013
Last Updated: 2008-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1455 participants
INTERVENTIONAL
2003-11-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
xaliproden (SR57746A)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild to moderate degree of severity of dementia as assessed by the Mini-Mental Status Examination score of 16 to 26 (inclusive)
* Potential participant may be treated with conventional Alzheimer's disease therapy and must be on a stable dose for at least 6 months prior to the randomization and during the entire study period
* Potential participant must have a reliable caregiver and must be living in a community or in an assisted living facility
* Mother tongue is English, Spanish or French (oral and written fluency)
* Signed informed consent from potential participant or legal representative and identified caregiver
Exclusion Criteria
* Potential participant with serious health problems other than Alzheimer's disease
* Use of an investigational drug within two months prior to randomization or during this study
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ICD CSD
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurological Physicians of Arizona, Inc.
Mesa, Arizona, United States
Pivotal Research Centers
Mesa, Arizona, United States
Pivotal Research Centers
Peoria, Arizona, United States
Northwest NeuroSpecialists
Tucson, Arizona, United States
Optimum Health Services
Oceanside, California, United States
Anderson Clinical Research
Redlands, California, United States
Univ. of CT Health Center
Farmington, Connecticut, United States
CNS Healthcare
Jacksonville, Florida, United States
Mayo Clinic
Jacksonville, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Memory Disorder Center
Pompano Beach, Florida, United States
Neurological Center
Fort Wayne, Indiana, United States
Vince and Associates Clinical Research
Overland Park, Kansas, United States
Hartford Research Group
Florence, Kentucky, United States
Lexington Clinic
Lexington, Kentucky, United States
LSUHSC Geriatric Psychiatry
New Orleans, Louisiana, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Synergy Medical
Saginaw, Michigan, United States
University Medical Center, Dept. of Psychiatry Clinical Trials
Jackson, Mississippi, United States
Radiant Research, Inc.
St Louis, Missouri, United States
Center For Emotional Fitness
Moorestown, New Jersey, United States
Ubhc/Umdnj667
Piscataway, New Jersey, United States
The Ohio State University
Columbus, Ohio, United States
The Clinical Trial Center
Jenkintown, Pennsylvania, United States
Radiant Research
Greer, South Carolina, United States
Alzheimer's Research & Clinical Programs
North Charleston, South Carolina, United States
Harmony Research, Inc
Johnson City, Tennessee, United States
R/D Clinical Research, Inc.
Lake Jackson, Texas, United States
Grayline Clinical Drug Trial
Wichita Falls, Texas, United States
The Innovative Clinical Research Center
Alexandria, Virginia, United States
Eastern Virginia Medical School - The Glennan Center For Geriatrics "Gerontology"
Norfolk, Virginia, United States
National Clinical Research, Inc
Richmond, Virginia, United States
sanofi-aventis Australia & New Zealand administrative office
Macquarie Park, New South Wales, , Australia
Sanofi-Aventis Administrative Office
Paris, , France
Sanofi-Aventis Administrative Office
Causeway Bay, , Hong Kong
Sanfoi-Aventis Administrative Office
Milan, , Italy
Sanofi-Aventis Administrative Office
Gouda, , Netherlands
Sanofi-Aventis Administrative Office
Singapore, , Singapore
Sanofi-Aventis Administrative Office
Midrand, , South Africa
Sanofi-Aventis Administrative Office
Barcelona, , Spain
Sanofi-Aventis Administrative Office
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SR57746A
Identifier Type: -
Identifier Source: secondary_id
EFC2724
Identifier Type: -
Identifier Source: org_study_id